Literature DB >> 26552975

Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.

Alasdair P MacGowan1, Alan R Noel1, Sharon G Tomaselli1, Donna Nicholls1, Karen E Bowker2.   

Abstract

Ceftolozane plus tazobactam is an antipseudomonal cephalosporin combined with tazobactam, an established beta-lactamase inhibitor, and has in vitro potency against a range of clinically important β-lactamase-producing bacteria, including most extended-spectrum-β-lactamase (ESBL)-positive Enterobacteriaceae. The pharmacodynamics of β-lactam-β-lactamase inhibitor combinations presents a number of theoretical and practical challenges, including modeling different half-lives of the compounds. In this study, we studied the pharmacodynamics of ceftolozane plus tazobactam against Escherichia coli and Pseudomonas aeruginosa using an in vitro pharmacokinetic model of infection. Five strains of E. coli, including three clinical strains plus two CTX-M-15 (one high and one moderate) producers, and five strains of P. aeruginosa, including two with OprD overexpression and AmpC β-lactamases, were employed. Ceftolozane MICs (E. coli, 0.12 to 0.25 mg/liter, and P. aeruginosa, 0.38 to 8 mg/liter) were determined in the presence of 4 mg/liter tazobactam. Dose ranging of ceftolozane (percentage of time in which the free-drug concentration exceeds the MIC [fT>MIC], 0 to 100%) plus tazobactam (human pharmacokinetics) was simulated every 8 hours, with half-lives (t1/2) of 2.5 and 1 h, respectively. Ceftolozane and tazobactam concentrations were confirmed by high-performance liquid chromatography (HPLC). The ceftolozane-plus-tazobactam fT>MIC values at 24 h for a static effect and a 1-log and 2-log drop in initial inoculum for E. coli were 27.8% ± 5.6%, 33.0% ± 5.6%, and 39.6% ± 8.5%, respectively. CTX-M-15 production did not affect the 24-h fT>MIC for E. coli strains. The ceftolozane-plus-tazobactam fT>MIC values for a 24-h static effect and a 1-log and 2-log drop for P. aeruginosa were 24.9% ± 3.0%, 26.6% ± 3.9%, and 31.2% ± 3.6%. Despite a wide range of absolute MICs, the killing remained predictable as long as the MICs were normalized to the corresponding fT>MIC. Emergence of resistance on 4× MIC plates and 8× MIC plates occurred maximally at an fT>MIC of 10 to 30% and increased as time of exposure increased. The fT>MIC for a static effect for ceftolozane plus tazobactam is less than that observed with other cephalosporins against E. coli and P. aeruginosa and is more similar to the fT>MIC reported for carbapenems.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26552975      PMCID: PMC4704154          DOI: 10.1128/AAC.00727-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Authors:  Yigong Ge; M J Whitehouse; Ian Friedland; George H Talbot
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Activity of cephalosporin CXA-101 (FR264205) and comparators against extended-spectrum-{beta}-lactamase-producing Pseudomonas aeruginosa.

Authors:  Christian G Giske; James Ge; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2009-05-27       Impact factor: 5.790

3.  In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.

Authors:  Catharine C Bulik; Henry Christensen; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

4.  Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Authors:  Christopher Lucasti; Ellie Hershberger; Benjamin Miller; Sara Yankelev; Judith Steenbergen; Ian Friedland; Joseph Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

Authors:  Brian VanScoy; Rodrigo E Mendes; Anthony M Nicasio; Mariana Castanheira; Catharine C Bulik; Olanrewaju O Okusanya; Sujata M Bhavnani; Alan Forrest; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

6.  Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan Noel; Sharon Tomaselli; Heather Elliott; Karen Bowker
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

7.  Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.

Authors:  Ronald N Jones; Rodrigo E Mendes; Helio S Sader
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

8.  Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.

Authors:  Helio S Sader; Paul R Rhomberg; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

9.  Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Authors:  A J Lepak; A Reda; K Marchillo; J Van Hecker; W A Craig; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

Review 10.  Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

Authors:  William A Craig
Journal:  Infect Dis Clin North Am       Date:  2003-09       Impact factor: 5.982

View more
  4 in total

1.  Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.

Authors:  Fabian Bernhard; Rajesh Odedra; Sylvie Sordello; Rossella Cardin; Samantha Franzoni; Cédric Charrier; Adam Belley; Peter Warn; Matthias Machacek; Philipp Knechtle
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 2.  Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.

Authors:  Stephanie E Giancola; Monica V Mahoney; Tiffany E Bias; Elizabeth B Hirsch
Journal:  Ther Clin Risk Manag       Date:  2016-05-19       Impact factor: 2.423

3.  Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model.

Authors:  María M Montero; Sandra Domene-Ochoa; Carla López-Causapé; Sonia Luque; Luisa Sorlí; Núria Campillo; Eduardo Padilla; Núria Prim; Lorena Ferrer-Alapont; Ariadna Angulo-Brunet; Santiago Grau; Antonio Oliver; Juan P Horcajada
Journal:  Sci Rep       Date:  2021-11-12       Impact factor: 4.379

4.  Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia.

Authors:  Jesus Ruiz; Alejandra Ferrada; Miguel Salavert; Mónica Gordon; Esther Villarreal; Álvaro Castellanos-Ortega; Paula Ramirez
Journal:  Dose Response       Date:  2020-01-29       Impact factor: 2.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.